MECP2 and breast cancer: Finally, it was confirmed that linc‐ROR promoted the progression of breast cancer and decreased the sensitivity of breast cancer cells to rapamycin by functioning as a ceRNA sponge for miR‐194‐3p, which targets MECP2.